NCT05721573COMPLETEDanonymous

A Phase II/III Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of ABC008 in the Treatment of Subjects With Inclusion Body Myositis

Sponsor

Source record

Abcuro, Inc.

Phase

Source record

PHASE2

Modality

AI-normalized

small molecule

Target

AI-normalized

ABC008

Indication / condition

AI-normalized

Inclusion Body Myositis

Intervention

Source record

ABC008

Source & freshness

Source record

NCT ID

NCT05721573

Original source

ClinicalTrials.gov

Source last updated

Jan 29, 2026

Ingested at

Jun 17, 2026

Internal sync

Jun 17, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record

View original source fields

NCT ID

NCT05721573

Title

A Phase II/III Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of ABC008 in the Treatment of Subjects With Inclusion Body Myositis

Sponsor

Abcuro, Inc.

Status

COMPLETED

Phase

PHASE2

Condition raw

Inclusion Body Myositis

Condition normalized

Inclusion Body Myositis

Modality raw

small molecule

Modality normalized

small molecule

Target raw

ABC008

Target normalized

ABC008

Interventions

ABC008

Public preview

Source record

A Phase II/III Randomized, Double-blind, Placebo-controlled, Multicenter Study to Determine the Efficacy and Safety of ABC008 in the Treatment of Subjects with Inclusion Body Myositis

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections

Patent/IP landscape with verified records when available

Board-ready PDF export with source provenance

Save to folders and synthesize multiple assets in premium workspace

Create account

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

A Phase II/III Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of ABC008 in the Treatment of Subjects With Inclusion Body Myositis

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 17, 2026

NCT ID

NCT05721573

Status

COMPLETED

Phase

PHASE2

Sponsor

Abcuro, Inc.

Executive brief

Investment-Ready Snapshot

A Phase II/III Randomized, Double-blind, Placebo-controlled, Multicenter Study to Determine the Efficacy and Safety of ABC008 in the Treatment of Subjects with Inclusion Body Myositis

Source & freshness

Provenance

SourceClinicalTrials.gov

Source updatedJan 29, 2026

Internal syncJun 17, 2026

Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT05721573

Indication

Inclusion Body Myositis

Modality

small molecule

Target

ABC008

Intervention

ABC008

Source record